Averitas develops small‑molecule therapeutics that selectively modulate the TRPV1 receptor to treat chronic neuropathic pain such as diabetic peripheral neuropathy and post‑herpetic neuralgia.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with neuropathic conditions such as diabetic peripheral neuropathy and postherpetic neuralgia often experience chronic, debilitating pain that is inadequately managed by existing first‑line therapies. The lack of affordable, mechanism‑based treatments leaves many individuals with unresolved pain and reduced quality of life.
Solution
Averitas focuses on developing small‑molecule therapeutics that selectively modulate the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor, a key driver of pain signaling in damaged peripheral nerves. By targeting the underlying pathophysiology of neuropathic pain, its candidates aim to provide effective relief while minimizing systemic side effects. The company emphasizes patient‑centric drug design to ensure oral dosing, straightforward administration, and cost‑effective manufacturing. Preclinical programs are built on a legacy of analgesic research, leveraging structure‑based drug design and pharmacokinetic optimization to create compounds suitable for chronic use. Clinical development plans target indications with high unmet need, such as diabetic peripheral neuropathy and postherpetic neuralgia, with the goal of delivering accessible therapies to patients worldwide.
Target Audience
Primary customers are pharmaceutical partners and healthcare providers seeking novel, mechanism‑based treatments for chronic neuropathic pain, particularly in diabetic peripheral neuropathy and postherpetic neuralgia patients.
Features
- Selective TRPV1 receptor modulators designed to attenuate nociceptive signaling in peripheral nerves
- Oral dosage forms optimized for once‑daily administration to support chronic treatment regimens
- Structure‑guided medicinal chemistry pipeline that balances potency, safety, and manufacturability
- Preclinical efficacy demonstrated in validated models of diabetic neuropathy and post‑herpetic neuralgia
- Cost‑focused development strategy to enable affordable pricing for large patient populations